Cargando…

Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study

OBJECTIVE: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. METHODS: The present 4-week, randomized, rater-blinded study included 25 patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woo, Young Sup, Park, Sung-Yong, Yoon, Bo-Hyun, Choi, Won-Seok, Wang, Sheng-Min, Bahk, Won-Myong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329105/ https://www.ncbi.nlm.nih.gov/pubmed/35879041 http://dx.doi.org/10.9758/cpn.2022.20.3.567

Ejemplares similares

Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
por: Bahk, W.-M., et al.
Publicado: (2023)

Repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia
por: Liu, Jin-Ling, et al.
Publicado: (2023)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial
por: Barnes, Thomas R.E., et al.
Publicado: (2018)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study
por: Liang, Ying, et al.
Publicado: (2016)

Comparison between Atomoxetine and OROS Methylphenidate as an Adjunctive to SSRIs in Attention-deficit/Hyperactivity Disorder Adults with Comorbid Partially Responsive Major Depressive Disorder: A Head-to-head, 12-week, Randomized, Rater-blinded Clinical Trial
por: Shim, Se-hoon, et al.
Publicado: (2022)

Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial
por: Stabell, L.A, et al.
Publicado: (2023)

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
por: Zhu, Ming-Huan, et al.
Publicado: (2022)

PS150. Comparative efficacy of various augmentation strategies for treatment-resistant depression: a meta-analysis of randomized controlled trials
por: Wang, Hee Ryung, et al.
Publicado: (2016)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
por: Liang, Ying, et al.
Publicado: (2017)

Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study
por: Kumar, Subodh, et al.
Publicado: (2014)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

The Diagnostic Stability of DSM-IV Diagnoses: An Examination of Major Depressive Disorder, Bipolar I Disorder, and Schizophrenia in Korean Patients
por: Kim, Won, et al.
Publicado: (2011)

Effectiveness and Tolerability of Korean Red Ginseng Augmentation in Major Depressive Disorder Patients with Difficult-to-treat in Routine Practice
por: Lee, Kyung Ho, et al.
Publicado: (2020)

F194. ASSOCIATION STUDY BETWEEN TREATMENT RESPONSE OF AMISULPRIDE AND DOPAMINE D3 RECEPTOR GENE POLYMORPHISMS
por: Lee, Kwanghun, et al.
Publicado: (2018)

Update on the management of symptoms in schizophrenia: focus on amisulpride
por: Mortimer, Ann M
Publicado: (2009)

Augmenting amisulpride with clozapine had led to unmasking of akathisia
por: Ray, Anirban, et al.
Publicado: (2012)

Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study
por: Kim, Yongmin, et al.
Publicado: (2016)

Evaluation of Efficacy, Safety, and Cognitive Profile of Amisulpride Per Se and Its Comparison with Olanzapine in Newly Diagnosed Schizophrenic Patients in an 8-Week, Double-Blind, Single-Centre, Prospective Clinical Trial
por: Pawar, Ganesh R., et al.
Publicado: (2012)

Relationship between Delusion of Theft and Cognitive Functions in Patients with Mild Alzheimer’s Disease
por: Na, Hae-Ran, et al.
Publicado: (2018)

Vitamin D Deficiency/Insufficiency among Inpatients with Depressive Symptoms
por: Woo, Young Sup, et al.
Publicado: (2019)

Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study
por: Ganguli, Rohan, et al.
Publicado: (2008)

Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients
por: Woo, Young Sup, et al.
Publicado: (2016)

Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
por: Men, Peng, et al.
Publicado: (2018)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

PM391. THE USE OF AMISULPRIDE IN TREATMENT OF PATIENTS WITH RESIDUAL SCHIZOPHRENIA
por: Janjic, Vladimir, et al.
Publicado: (2016)

A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
por: Abdall-Razak, Ali, et al.
Publicado: (2019)

Hyperprolactinaemia with amisulpride
por: Raj, Rajnish, et al.
Publicado: (2008)

Title- Augmenting Amisulpride With Clozapine Leading To Akathisia: A Case Report
Publicado: (2022)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro)
por: Kjelby, Eirik, et al.
Publicado: (2023)

Analysis of Gut Microbiota in Patients with Exacerbated Symptoms of Schizophrenia following Therapy with Amisulpride: A Pilot Study
por: Zheng, Jinchi, et al.
Publicado: (2022)

Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
por: Leweke, F. Markus, et al.
Publicado: (2021)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

M41. TRAJECTORIES AND PREDICTORS OF OUTCOME IN SCHIZOPHRENIA: THE BENEFICIAL ROLE OF AMISULPRIDE
por: Drosos, Petros, et al.
Publicado: (2020)

Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders
por: de Haan, Lieuwe, et al.
Publicado: (2023)

Amisulpride Augmentation for Clozapine-Refractory Positive Symptoms: Additional Benefit in Reducing Hypersialorrhea
por: Bogorni, Fabiani, et al.
Publicado: (2015)

Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea
por: Woo, Young Sup, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_79ei41masbsvb612din7f0dq77